Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
EMBO J ; 20(17): 4762-73, 2001 Sep 03.
Article in English | MEDLINE | ID: mdl-11532940

ABSTRACT

Vascular endothelial growth factor receptor-3 (VEGFR-3/Flt4) binds two known members of the VEGF ligand family, VEGF-C and VEGF-D, and has a critical function in the remodelling of the primary capillary vasculature of midgestation embryos. Later during development, VEGFR-3 regulates the growth and maintenance of the lymphatic vessels. In the present study, we have isolated and cultured stable lineages of blood vascular and lymphatic endothelial cells from human primary microvascular endothelium by using antibodies against the extracellular domain of VEGFR-3. We show that VEGFR-3 stimulation alone protects the lymphatic endothelial cells from serum deprivation-induced apoptosis and induces their growth and migration. At least some of these signals are transduced via a protein kinase C-dependent activation of the p42/p44 MAPK signalling cascade and via a wortmannin-sensitive induction of Akt phosphorylation. These results define the critical role of VEGF-C/VEGFR-3 signalling in the growth and survival of lymphatic endothelial cells. The culture of isolated lymphatic endothelial cells should now allow further studies of the molecular properties of these cells.


Subject(s)
Apoptosis/physiology , Endothelial Growth Factors/pharmacology , Endothelial Growth Factors/physiology , Endothelium, Vascular/physiology , Endothelium/physiology , Lymphatic System/physiology , MAP Kinase Signaling System/physiology , Receptor Protein-Tyrosine Kinases/physiology , Receptors, Growth Factor/physiology , Apoptosis/drug effects , Biosensing Techniques , Capillaries/embryology , Capillaries/physiology , Cell Division , Cell Movement , Cell Survival , Cells, Cultured , Endothelium/cytology , Endothelium, Vascular/cytology , Enzyme Activation , Humans , Kinetics , Lymphatic System/cytology , Microcirculation/physiology , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3 , Mitogen-Activated Protein Kinases/metabolism , Protein Kinase C/metabolism , RNA, Messenger/genetics , Receptor Protein-Tyrosine Kinases/genetics , Receptors, Growth Factor/genetics , Receptors, Vascular Endothelial Growth Factor , Skin/blood supply , Umbilical Veins , Vascular Endothelial Growth Factor C , Vascular Endothelial Growth Factor D , Vascular Endothelial Growth Factor Receptor-3
2.
Cancer Res ; 61(17): 6511-6, 2001 Sep 01.
Article in English | MEDLINE | ID: mdl-11522648

ABSTRACT

Endostatin, a M(r) 20,000 fragment of collagen XVIII, is able to inhibit angiogenesis and induce apoptosis in endothelial cells in vivo. We analyzed the effectsof recombinant endostatin on human microvascular endothelial cells, focusing on pericellular plasminogen activation and its targeting by the focal adhesion-associated cytoskeletal structures. Analysis of the proteolytic plasminogen activator system revealed that endostatin modulates the distribution of soluble and cell surface-associated urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor, type 1 (PAI-1). Casein zymographic and immunoprecipitation analyses indicated that endostatin exerts its effects by decreasing the levels of soluble uPA and PAI-1 and their complexes in a dose-dependent manner. Immunofluorescence analysis of cell surface-associated uPA indicated that endostatin treatment caused the redistribution of receptor-bound uPA from focal contacts, resulting in diffuse cell surface staining. In accordance with this observation, immunofluorescence staining of the urokinase receptor revealed that endostatin treatment removed uPAR from focal adhesions. Accordingly, endostatin caused a rapid disassembly of focal adhesions as observed by immunofluorescence analysis of the focal adhesion proteins vinculin and paxillin. A prominent change in the cytoskeletal architecture was observed as the actin stress fiber network was dissociated in response to endostatin treatment. The effect of focal adhesion disassembly was reversible, persisting from 1 h up to 6 h. Our results suggest that the antiangiogenic activity of endostatin involves the modulation of focal adhesions and actin stress fibers and the down-regulation of the urokinase plasminogen activator system.


Subject(s)
Actins/metabolism , Angiogenesis Inhibitors/pharmacology , Collagen/pharmacology , Endothelium, Vascular/drug effects , Focal Adhesions/drug effects , Peptide Fragments/pharmacology , Urokinase-Type Plasminogen Activator/metabolism , Apoptosis/drug effects , Cell Adhesion/drug effects , Cell Membrane/drug effects , Cell Membrane/metabolism , Cell Movement/drug effects , Cells, Cultured , Collagen Type XVIII , Cytoskeleton/drug effects , Cytoskeleton/metabolism , Endostatins , Endothelium, Vascular/cytology , Endothelium, Vascular/metabolism , Focal Adhesions/metabolism , Humans , Plasminogen Activator Inhibitor 1/metabolism , Receptors, Cell Surface/metabolism , Receptors, Urokinase Plasminogen Activator , Recombinant Proteins/pharmacology , Solubility
3.
EMBO J ; 20(6): 1223-31, 2001 Mar 15.
Article in English | MEDLINE | ID: mdl-11250889

ABSTRACT

Vascular endothelial growth factor receptor-3 (VEGFR-3) has an essential role in the development of embryonic blood vessels; however, after midgestation its expression becomes restricted mainly to the developing lymphatic vessels. The VEGFR-3 ligand VEGF-C stimulates lymphangiogenesis in transgenic mice and in chick chorioallantoic membrane. As VEGF-C also binds VEGFR-2, which is expressed in lymphatic endothelia, it is not clear which receptors are responsible for the lymphangiogenic effects of VEGF-C. VEGF-D, which binds to the same receptors, has been reported to induce angiogenesis, but its lymphangiogenic potential is not known. In order to define the lymphangiogenic signalling pathway we have created transgenic mice overexpressing a VEGFR-3-specific mutant of VEGF-C (VEGF-C156S) or VEGF-D in epidermal keratinocytes under the keratin 14 promoter. Both transgenes induced the growth of lymphatic vessels in the skin, whereas the blood vessel architecture was not affected. Evidence was also obtained that these growth factors act in a paracrine manner in vivo. These results demonstrate that stimulation of the VEGFR-3 signal transduction pathway is sufficient to induce specifically lymphangiogenesis in vivo.


Subject(s)
Endothelial Growth Factors/metabolism , Lymphatic System/metabolism , Lymphokines/metabolism , Receptor Protein-Tyrosine Kinases/metabolism , Receptors, Growth Factor/metabolism , Skin/metabolism , Animals , Half-Life , Hyperplasia , Lymphatic System/growth & development , Lymphatic System/pathology , Mice , Mice, Transgenic , Paracrine Communication , Receptor Protein-Tyrosine Kinases/genetics , Receptors, Growth Factor/genetics , Recombinant Proteins/metabolism , Signal Transduction , Skin/blood supply , Skin/growth & development , Skin/pathology , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factor C , Vascular Endothelial Growth Factor D , Vascular Endothelial Growth Factor Receptor-3 , Vascular Endothelial Growth Factors
4.
Nat Med ; 7(2): 199-205, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11175851

ABSTRACT

The lymphatic vasculature transports extravasated tissue fluid, macromolecules and cells back into the blood circulation. Recent reports have focused on the molecular mechanisms regulating the lymphatic vessels. Vascular endothelial growth factor (VEGF)-C and VEGF-D have been shown to stimulate lymphangiogenesis and their receptor, VEGFR-3, has been linked to human hereditary lymphedema. Here we show that a soluble form of VEGFR-3 is a potent inhibitor of VEGF-C/VEGF-D signaling, and when expressed in the skin of transgenic mice, it inhibits fetal lymphangiogenesis and induces a regression of already formed lymphatic vessels, though the blood vasculature remains normal. Transgenic mice develop a lymphedema-like phenotype characterized by swelling of feet, edema and dermal fibrosis. They survive the neonatal period in spite of a virtually complete lack of lymphatic vessels in several tissues, and later show regeneration of the lymphatic vasculature, indicating that induction of lymphatic regeneration may also be possible in humans.


Subject(s)
Lymphedema/pathology , Neovascularization, Pathologic , Receptor Protein-Tyrosine Kinases/metabolism , Receptors, Growth Factor/metabolism , Signal Transduction , Animals , Cell Line , Endothelial Growth Factors/genetics , Endothelial Growth Factors/metabolism , Humans , Lymph Nodes/blood supply , Mice , Mice, Transgenic , Phenotype , Receptor Protein-Tyrosine Kinases/genetics , Receptors, Growth Factor/genetics , Solubility , Vascular Endothelial Growth Factor C , Vascular Endothelial Growth Factor D , Vascular Endothelial Growth Factor Receptor-3
5.
Proc Natl Acad Sci U S A ; 98(3): 1024-9, 2001 Jan 30.
Article in English | MEDLINE | ID: mdl-11158588

ABSTRACT

Endostatin, a fragment of collagen XVIII, is a potent antagonist of angiogenesis and inhibitor of tumor growth in mouse models. At present, the mechanism of action of endostatin is unknown. We show here that recombinantly produced human endostatin interacts with alpha(5)- and alpha(v)-integrins on the surface of human endothelial cells. We further demonstrate that the endostatin-integrin interaction is of functional significance in vitro, as we found that immobilized endostatin supports endothelial cell survival and migration in an integrin-dependent manner. Soluble endostatin in turn inhibits integrin-dependent endothelial cell functions, such as cell migration. Taken together, these results implicate integrins as potential targets for endostatin function and support the importance of integrins in endothelial cell biology and angiogenesis.


Subject(s)
Angiogenesis Inhibitors/pharmacology , Antigens, CD/physiology , Collagen/pharmacology , Collagen/physiology , Endothelium, Vascular/physiology , Peptide Fragments/pharmacology , Peptide Fragments/physiology , Animals , Cell Adhesion/drug effects , Cell Movement/drug effects , Cells, Cultured , Collagen/chemistry , Collagen Type XVIII , Edetic Acid/pharmacology , Endostatins , Endothelium, Vascular/cytology , Epidermal Growth Factor/pharmacology , Fibroblast Growth Factor 2/pharmacology , Focal Adhesion Kinase 1 , Focal Adhesion Protein-Tyrosine Kinases , Humans , Integrin alpha5 , Integrin alphaV , Kinetics , Mice , Oligopeptides/pharmacology , Phosphorylation , Protein-Tyrosine Kinases/metabolism , Recombinant Proteins/metabolism , Umbilical Veins
6.
Mod Pathol ; 13(2): 180-5, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10697276

ABSTRACT

Recently, a novel monoclonal antibody to vascular endothelial growth factor receptor 3 (VEGFR-3), a tyrosine kinase receptor expressed almost exclusively by lymphatic endothelium in the adult, has been shown to react with a small number of cases of Kaposi's sarcoma (KS) and cutaneous lymphangiomas. We sought to extend these studies to a large number of well-characterized vascular neoplasms to evaluate diagnostic uses of this antibody and to determine whether it defines them in a thematic fashion. Formalin-fixed, paraffin-embedded sections from 70 vascular tumors were immunostained with antibodies to VEGFR-3 von Willebrand factor (vWF), and CD31. Anti-VEGFR-3 was positive in 23 of 24 KS, 8 of 16 angiosarcomas (AS), 6 of 6 kaposiform hemangioendotheliomas, 4 of 4 Dabska tumors, and 2 of 13 hemangiomas. Positively staining angiosarcomas were characterized either by a prominent lymphocytic component, a hobnail endothelial cell similar to that encountered in the Dabska tumor, or spindled areas resembling KS. No VEGFR-3 expression was noted in any cases of epithelioid hemangioendothelioma, pyogenic granuloma, littoral angioma, or stasis dermatitis. vWF expression was seen in 10 of 13 KS; 13 of 14 AS; 4 of 5 kaposiform hemangioendotheliomas; and all Dabska tumors, hemangiomas, lymphangiomas, epithelioid hemangioendotheliomas, vascular malformations, stasis dermatitis, and splenic littoral angiomas. CD31 expression was present in 12 of 13 KS, 13 of 14 AS, and in all other cases. Expression of VEGFR-3 is a very sensitive marker of KS, kaposiform, and Dabska-type hemangioendotheliomas, suggesting that all show at least partial lymphatic endothelial differentiation. Expression of VEGFR-3 does not reliably discriminate KS from AS. However, the expression of VEGFR-3 by certain AS having Kaposi-like areas, a prominent lymphocytic infiltrate, or hobnail endothelium may define subset(s) having phenotypic, if not pathogenetic and biologic, differences.


Subject(s)
Hemangioendothelioma/metabolism , Hemangiosarcoma/metabolism , Receptor Protein-Tyrosine Kinases/metabolism , Receptors, Cell Surface/metabolism , Sarcoma, Kaposi/metabolism , Vascular Neoplasms/metabolism , Biomarkers, Tumor/metabolism , Endothelium, Vascular/metabolism , Endothelium, Vascular/pathology , Hemangioendothelioma/blood supply , Hemangioendothelioma/pathology , Hemangiosarcoma/blood supply , Hemangiosarcoma/pathology , Humans , Lymphatic System/metabolism , Lymphatic System/pathology , Sarcoma, Kaposi/blood supply , Sarcoma, Kaposi/pathology , Vascular Endothelial Growth Factor Receptor-3 , Vascular Neoplasms/blood supply , Vascular Neoplasms/pathology
8.
Cancer Res ; 59(19): 4984-9, 1999 Oct 01.
Article in English | MEDLINE | ID: mdl-10519412

ABSTRACT

Kaposi's sarcoma-associated herpesvirus (KSHV) has a key etiological role in development of Kaposi's sarcoma (KS). v-Cyclin is a KSHV-encoded homologue to D-type cyclins that associates with cellular cyclin-dependent kinase 6 (CDK6). v-Cyclin promotes S-phase entry of quiescent cells and has been suggested to execute functions of both D- and E-type cyclins. In this study, expression of v-cyclin in cells with elevated levels of CDK6 led to apoptotic cell death after the cells entered S phase. The cell death required the kinase activity of CDK6 because cells expressing a kinase-deficient form of CDK6 did not undergo apoptosis upon v-cyclin expression. Studies on the mechanisms involved in this caspase-3-mediated apoptosis indicated that it was independent of cellular p53 or pRb status, and it was not suppressed by Bcl-2. In contrast, the KSHV-encoded v-Bcl-2 efficiently suppressed v-cyclin-/CDK6-induced apoptosis, demonstrating a marked difference in the antiapoptotic properties of c-Bcl-2 and v-Bcl-2. In KS lesions, high CDK6 expression was confined to a subset of cells, some of which displayed signs of apoptosis. These results suggest that v-cyclin may exert both growth-promoting and apoptotic functions in KS, depending on factors regulating CDK6 and v-Bcl-2 levels.


Subject(s)
Apoptosis/physiology , Cyclin-Dependent Kinases , Cyclins/genetics , Cyclins/metabolism , Herpesvirus 8, Human/genetics , Protein Serine-Threonine Kinases/metabolism , Sarcoma, Kaposi/pathology , Animals , Apoptosis/drug effects , Bone Neoplasms , Caspase 3 , Caspases/metabolism , Cell Line , Cyclin-Dependent Kinase 6 , Cysteine Proteinase Inhibitors/pharmacology , Enzyme Inhibitors/pharmacology , Herpesvirus 8, Human/physiology , Humans , Molecular Sequence Data , Oligopeptides/pharmacology , Osteosarcoma , Proto-Oncogene Proteins c-bcl-2/metabolism , Retinoblastoma Protein/metabolism , Sarcoma, Kaposi/enzymology , Staurosporine/pharmacology , Tumor Cells, Cultured , Viral Proteins
9.
J Biol Chem ; 274(39): 27617-22, 1999 Sep 24.
Article in English | MEDLINE | ID: mdl-10488101

ABSTRACT

Recent evidence suggesting vascular endothelial growth factor-C (VEGF-C), which is a regulator of lymphatic and vascular endothelial development, raised the question whether this molecule could be involved in Kaposi's sarcoma (KS), a strongly angiogenic and inflammatory tumor often associated with infection by human immunodeficiency virus-1. This disease is characterized by the presence of a core constituted of three main populations of "spindle" cells, having the features of lymphatic/vascular endothelial cells, macrophagic/dendritic cells, and of a mixed macrophage-endothelial phenotype. In this study we evaluated the biological response of KS cells to VEGF-C, using an immortal cell line derived from a KS lesion (KS IMM), which retains most features of the parental tumor and can induce KS-like sarcomas when injected subcutaneously in nude mice. We show that VEGFR-3, the specific receptor for VEGF-C, is expressed by KS IMM cells grown in vitro and in vivo. In vitro, VEGF-C induces the tyrosine phosphorylation of VEGFR-2, a receptor also for VEGF-A, as well as that of VEGFR-3. The activation of these two receptors in KS IMM cells is followed by a dose-responsive mitogenic and motogenic response. The stimulation of KS IMM cells with a mutant VEGF-C unable to bind and activate VEFGR-2 resulted in no proliferative response and in a weak motogenic stimulation, suggesting that VEGFR-2 is essential in transducing a proliferative signal and cooperates with VEGFR-3 in inducing cell migration. Our data add new insights on the pathogenesis of KS, suggesting that the involvement of endothelial growth factors may not only determine KS-associated angiogenesis, but also play a critical role in controlling KS cell growth and/or migration and invasion.


Subject(s)
Endothelial Growth Factors/pharmacology , Endothelium, Vascular/cytology , Sarcoma, Kaposi/pathology , Sarcoma, Kaposi/physiopathology , Animals , Cell Division/drug effects , Cells, Cultured , Chemotaxis/drug effects , Endothelium, Vascular/drug effects , Endothelium, Vascular/physiology , Humans , Mice , Mice, Nude , Mutagenesis, Site-Directed , Phosphorylation , Receptor Protein-Tyrosine Kinases/genetics , Receptor Protein-Tyrosine Kinases/physiology , Receptors, Cell Surface/genetics , Receptors, Cell Surface/physiology , Recombinant Proteins/pharmacology , Transplantation, Heterologous , Tumor Cells, Cultured , Tyrosine , Umbilical Veins , Vascular Endothelial Growth Factor C , Vascular Endothelial Growth Factor Receptor-3
10.
Semin Cancer Biol ; 9(3): 211-20, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10343072

ABSTRACT

Angiogenesis, the formation of new blood vessels from pre--existing ones, is central for both normal development and homeostasis as well as in certain pathological conditions. The vascular endothelial growth factors (VEGFs) and their receptors are prime regulators of both physiological and pathological angiogenesis. The different VEGFs have overlapping but specific roles in controlling the growth of new blood vessels. The VEGF receptors transduce signals mediating endothelial cell proliferation, migration, organization into functional vessels and remodeling of the vessel network. In recent years, rapid progress has been made in understanding the receptor-ligand interactions that orchestrate the neovascularization process.


Subject(s)
Endothelial Growth Factors/physiology , Lymphokines/physiology , Neovascularization, Pathologic/etiology , Neovascularization, Physiologic , Receptor Protein-Tyrosine Kinases/physiology , Receptors, Growth Factor/physiology , Animals , Humans , Neoplasms/blood supply , Receptors, Vascular Endothelial Growth Factor , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
11.
Proc Natl Acad Sci U S A ; 96(6): 3071-6, 1999 Mar 16.
Article in English | MEDLINE | ID: mdl-10077638

ABSTRACT

Orf virus, a member of the poxvirus family, produces a pustular dermatitis in sheep, goats, and humans. The lesions induced after infection with orf virus show extensive proliferation of vascular endothelial cells, dilation of blood vessels and dermal swelling. An explanation for the nature of these lesions may lie in the discovery that orf virus encodes an apparent homolog of the mammalian vascular endothelial growth factor (VEGF) family of molecules. These molecules mediate endothelial cell proliferation, vascular permeability, angiogenesis, and lymphangiogenesis via the endothelial cell receptors VEGFR-1 (Flt1), VEGFR-2 (KDR/Flk1), and VEGFR-3 (Flt4). The VEGF-like protein of orf virus strain NZ2 (ORFV2-VEGF) is most closely related in primary structure to VEGF. In this study we examined the biological activities and receptor specificity of the ORFV2-VEGF protein. ORFV2-VEGF was found to be a disulfide-linked homodimer with a subunit of approximately 25 kDa. ORFV2-VEGF showed mitogenic activity on bovine aortic and human microvascular endothelial cells and induced vascular permeability. ORFV2-VEGF was found to bind and induce autophosphorylation of VEGFR-2 and was unable to bind or activate VEGFR-1 and VEGFR-3, but bound the newly identified VEGF165 receptor neuropilin-1. These results indicate that, from a functional viewpoint, ORFV2-VEGF is indeed a member of the VEGF family of molecules, but is unique, however, in that it utilizes only VEGFR-2 and neuropilin-1.


Subject(s)
Endothelial Growth Factors/metabolism , Lymphokines/metabolism , Nerve Tissue Proteins/metabolism , Orf virus/metabolism , Receptor Protein-Tyrosine Kinases/metabolism , Receptors, Growth Factor/metabolism , Viral Proteins/metabolism , Amino Acid Sequence , Animals , COS Cells , Cattle , Endothelial Growth Factors/genetics , Humans , Lymphokines/genetics , Molecular Sequence Data , Neuropilin-1 , Protein Binding , Receptors, Vascular Endothelial Growth Factor , Sequence Alignment , Sequence Homology, Amino Acid , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors , Viral Proteins/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...